Steris (FRA:2TG) Other Financing: €27 Mil (TTM As of Mar. 2026)


FRA:2TG Steris PLC FRA:2TG
85 GF Score
Price €183.20
GF Value €235.65
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Steris Other Financing?

Steris FRA:2TG +3.44% 85 Other Financing is €27 Mil as of Mar. 2026. GuruFocus rates FRA:2TG with a GF Score™ of 85/100 and a GF Value™ of €235.65 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Steris's Other Financing for the three months ended in Mar. 2026 was €0 Mil.

Steris's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €27 Mil.

Steris Other Financing Historical Data

* Premium members only.

The historical data trend for Steris's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steris Other Financing Chart

Steris Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.96 -0.41 5.24 21.46 26.90

Steris Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.98 6.39 11.96 0.35
FRA:2TG
85GF Score
Steris PLC FRA:2TG
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Steris Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €27 Mil mean?
Steris (FRA:2TG) has a Other Financing of €27 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Steris and its competitors.
Is Steris' Other Financing too high?
Steris' current Other Financing is €27 Mil. Overall, Steris has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Steris' Other Financing compare to ZBH and DXCM?
Steris' Other Financing of €27 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Steris and its competitors. Steris's current Other Financing is €27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Based on GuruFocus' analysis, Steris (FRA:2TG) is currently considered Modestly Undervalued. The stock's GF Value™ is €235.65, compared to a current price of €183.20 — trading 22.3% below its estimated fair value. The current Other Financing is €27 Mil. Steris' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Steris (FRA:2TG), the current Other Financing is €27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Steris (FRA:2TG) Overvalued in 2026?

Based on GuruFocus' analysis, Steris stock appears to be undervalued. The current stock price of €183.20 is trading 22.3% below its estimated GF Value™ of €235.65. GuruFocus considers Steris to be Modestly Undervalued.

Key valuation signals for FRA:2TG:

  • Other Financing: €27 Mil
  • GF Value™: €235.65 vs. price of €183.20 (22.3% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the FRA:2TG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Steris Business Description

Other Exchanges STE:USAS1TE34:Brazil
Address 70 Sir John Rogerson\'s Quay, Dublin, IRL, D02 R296
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
85GF Score

Get the complete analysis for FRA:2TG

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€183.20
Price
€235.65
GF Value